Biotech Industry Study Reports Big Gains in M&A, IPOs
Consulting firm BDO USA's "2015 BDO Biotech Briefing" examined recent annual report filings of stocks included on the Nasdaq Biotechnology Index.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 236
Anthem Affirms Guidance
Anthem is trying to convey the message that the problems of UnitedHealth Group are not its problem. At least that is what the company's guidance suggests.
4 Biopharma and Pharmaceutical Stocks With Game-Changing Catalysts Coming
A new Jefferies research report highlights four top companies that could be looking at catalysts that in the very near term could have a huge impact on the stocks.
Axsome Therapeutics Quietly Enters Market in IPO
Axsome Therapeutics entered the market on Thursday morning at a price below the previously announced expected pricing range.
Celladon Soars on Proposed Merger Agreement
Celladon and Eiger BioPharmaceuticals have announced that they have entered into a definitive merger agreement.
UnitedHealth Warning Creates Huge Spillover, With Big Implications Ahead
We have word from UnitedHealth Group in an earnings warning that could be a serious blow to at least part of ACA/Obamacare.
KaloBios Skyrockets After Martin Shkreli Takes a Majority Stake
Turing Pharmaceuticals CEO Martin Shkreli took a major stake in this small biopharma company KaloBios Pharmaceuticals over the course of this week.
Jefferies Reveals Top 5 Pharma Stock Picks for Growth and Dividends
Jefferies has updated the thesis behind its "Top 5 for 2015" pharmaceutical stock picks
Ocera Therapeutics Rises on Positive Phase 1 Results
Ocera Therapeutics broke out in Tuesday's trading session following positive results from a clinical study.
What Perrigo and Teva Can Learn From Mylan’s Share Repurchase
Mylan announced Monday that it would be conducting a share repurchase for up to $1 billion, in a much faster timeline for repurchasing than most companies would give.
Clovis More Than Halves on FDA Hurdle
Clovis Oncology was leading the bears in Monday’s trading session on news that its lung cancer drug may be delayed.
Merck Prepares to Break Into HCV Market With Recent Study Results
Merck is joining the likes of Gilead Sciences in producing hepatitis C vaccines, but it is still in the early clinical stages.
Why Being Added into the S&P 500 Matters So Much for Illumina
Being added to the S&P 500 Index comes with a certain amount of prestige. It can also come with a big financial boost in some cases. When it comes to what that means for Illumina Inc.…
7 BioHealth Movers That Cannot Be Ignored
The biotech companies 24/7 Wall St. has picked stood out from the rest with incredible gains or losses over the course of the past week.
Alcobra Gears Up for Secondary Offering
Alcobra has announced the pricing of its underwritten secondary offering for more than 6 million shares.